Related Experiment Video

Updated: Jun 2, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Yuan Yuan1, Yu-Min Liao, Chung-Tsen Hsueh

  • 1Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA.

Journal of Hematology & Oncology
|April 21, 2011
PubMed

Insights

This review covers MDM2, ALK, and PARP inhibitors in clinical development. These targeted therapies show promise for various cancers, including lung, breast, and ovarian cancers, with ongoing research for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MDM2 (murine double minute 2) inhibitors target p53 degradation.
  • ALK (anaplastic lymphoma kinase) fusions are implicated in non-small cell lung cancer (NSCLC).
  • PARP (poly [ADP-ribose] polymerase) inhibitors are involved in DNA repair pathways.

Purpose of the Study:

  • To review preclinical and clinical data for MDM2, ALK, and PARP inhibitors.
  • To highlight the therapeutic potential of these targeted agents in various cancers.
  • To summarize current clinical development and early findings.

Main Methods:

  • Review of preclinical data.
  • Analysis of clinical trial results.
  • Literature search for MDM2, ALK, and PARP inhibitors.

Main Results:

  • MDM2 inhibitors (JNJ-26854165, RO5045337) are in clinical development.
  • ALK inhibitor Crizotinib shows activity in NSCLC with EML4-ALK fusion.
  • PARP inhibitors (BSI-201, Olaparib) demonstrate efficacy in breast and ovarian cancers.

Conclusions:

  • Targeted inhibitors of MDM2, ALK, and PARP represent a promising area in cancer therapy.
  • Clinical development is advancing for these agents across multiple cancer types.
  • Further investigation is warranted to optimize their use and improve patient outcomes.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...